EPS for Replimune Group, Inc. (REPL) Expected At $-0.19

November 11, 2018 - By James Guidry

Analysts expect Replimune Group, Inc. (NASDAQ:REPL) to report $-0.19 EPS on November, 29.After having $-2.02 EPS previously, Replimune Group, Inc.’s analysts see -90.59 % EPS growth. The stock decreased 3.29% or $0.49 during the last trading session, reaching $14.41. About 10,999 shares traded. Replimune Group, Inc. (NASDAQ:REPL) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company has market cap of $454.69 million. The firm uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. It currently has negative earnings. The Company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Another recent and important Replimune Group, Inc. (NASDAQ:REPL) news was published by Benzinga.com which published an article titled: “44 Biggest Movers From Yesterday” on October 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: